Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Robinhood Markets, Inc. (HOOD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Robinhood Markets, Inc.Trade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Robinhood Markets, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Robinhood Markets, Inc. trades at $101.68 (market cap $89.13B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.

HOODXBI
Market Cap
$89.13B
Sector
TechnologyBroad Market / Factor
52-Week High
$152.46$164.28
52-Week Low
$65.16$85.16
Enterprise Value
$90.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Robinhood Markets, Inc.

Robinhood Markets (HOOD) trades at $99.41, down 0.55% on the day, with technical indicators showing a bearish short-term trend. The stock has strong fundamentals, including 2025 revenue of $4.47 billion and net income of $1.88 billion, with a net margin of 42.09%. Recent news highlights institutional selling and CFO share disposals, but analyst consensus remains bullish with a $113.21 price target. Cash flow improved significantly in 2025 to $1.20 billion net.

The outlook for HOOD is mixed: strong profitability and growth support upside potential, but near-term technical weakness and insider selling pose risks. Investors should weigh robust financials against market sentiment and competitive pressures in the fintech sector.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.

Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Robinhood Markets, Inc.

Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.

Read more on HOOD

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI